Literature DB >> 14702169

Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas.

D Stefanou1, A Batistatou, E Arkoumani, E Ntzani, N J Agnantis.   

Abstract

Recent studies have demonstrated that tumor angiogenesis is a prognostic factor for various malignant neoplasms. Specifically, in non-small-cell lung carcinomas (NSCLCs) most reports show an association between neovascularization and vascular endothelial growth factor (VEGF) expression as well as the presence of metastases and survival, although a few reports do not agree with these findings. Angiogenesis is not clearly characterized in small-cell lung carcinomas (SCLCs), since they are rarely treated by surgery, and thus the available tissue for biological characterization is sparse. The aim of the present study was to investigate angiogenesis and the expression of VEGF in lung tumors. We examined 88 non-small-cell and 39 small-cell lung carcinomas. Angiogenesis was estimated by determining microvessel counts, with the use of anti-CD31 and anti-factor VIII antibodies and expression of VEGF was also evaluated immunohistochemically. Our data showed that in NSCLCs angiogenesis was more prominent in poorly-differentiated neoplasms and correlated with VEGF expression, therefore it is at least in part mediated by the latter. Interestingly, in SCLCs a higher vascularization was noted. However, there was no strong association with VEGF expression. Thus, small-cell lung carcinoma may represent a suitable neoplasm for testing antiangiogenic drugs in combination with chemotherapy. Nevertheless, antiangiogenic therapy should not be targeted specifically to the VEGF pathway, since in SCLCs other mediators of angiogenesis may be important as well.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14702169     DOI: 10.14670/HH-19.37

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  19 in total

1.  Difference in intraosseous blood vessel volume and number in osteoporotic model mice induced by spinal cord injury and sciatic nerve resection.

Authors:  Wen-Ge Ding; Wei-hong Yan; Zhao-Xiang Wei; Jin-Bo Liu
Journal:  J Bone Miner Metab       Date:  2011-11-08       Impact factor: 2.626

Review 2.  Genomics of lung cancer may change diagnosis, prognosis and therapy.

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

Review 3.  Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities.

Authors:  Zhiliang Cheng; Ajlan Al Zaki; James Z Hui; Vladimir R Muzykantov; Andrew Tsourkas
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

Review 4.  Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities.

Authors:  Zhiyong Wang; Gang Liu; Hairong Zheng; Xiaoyuan Chen
Journal:  Biotechnol Adv       Date:  2013-09-05       Impact factor: 14.227

Review 5.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

Review 6.  Targeted therapies for lung cancer: clinical experience and novel agents.

Authors:  Jill E Larsen; Tina Cascone; David E Gerber; John V Heymach; John D Minna
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

7.  Clinical application of pharmacokinetic analysis as a biomarker of solitary pulmonary nodules: dynamic contrast-enhanced MR imaging.

Authors:  Hatsuho Mamata; Junichi Tokuda; Ritu R Gill; Robert F Padera; Robert E Lenkinski; David J Sugarbaker; James P Butler; Hiroto Hatabu
Journal:  Magn Reson Med       Date:  2012-01-09       Impact factor: 4.668

8.  Blood vessel density in Basal cell carcinomas and benign trichogenic tumors as a marker for differential diagnosis in dermatopathology.

Authors:  Julia Winter; Hermann Kneitz; Eva-B Bröcker
Journal:  J Skin Cancer       Date:  2010-10-07

Review 9.  Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).

Authors:  Gerald Schmid-Bindert
Journal:  Target Oncol       Date:  2013-02-01       Impact factor: 4.493

Review 10.  An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.

Authors:  M Majem; C Pallarès
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.